AMRN - Amarin Corporation plc
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.1900 |
| Open | 1.1900 |
| Bid | 0.0000 x 3100 |
| Ask | 0.0000 x 1300 |
| Day's Range | 1.1600 - 1.2200 |
| 52 Week Range | 1.0400 - 2.2300 |
| Volume | |
| Avg. Volume | 2,941,890 |
| Market Cap | 485.258M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2200 |
| Earnings Date | May 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.13 |
Fair Value
Related Research
InvestorPlace3 Biotech Stocks to Avoid Like the Plague
Biotech stocks have gotten caught up in the broader technology sector sell-off. The benchmark iShares Biotechnology ETF (NYSEARCA:IBB) has fallen from a peak of $175 in 2021 to just $130 today. There are few signs of a biotech stock bubble at this point. That said, even with the sector at an overall discount, that’s not an all-clear for the whole sector. Many of the worst biotech stocks either have a drug prospect that is unlikely to get FDA approval or one that simply never garners much commerc
GlobeNewswireAmarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action-- DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) on coronary physiology, which was published in the European Heart Journal - Cardiov
Motley FoolAmarin Plc (AMRN) Q1 2023 Earnings Call Transcript
Greetings and welcome to Amarin Corporation's conference call to discuss its first-quarter 2023 financial results and operational update. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided under federal securities law.
ZacksAmarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
- GlobeNewswire
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales; Pricing & Reimbursement Discussions in Key European Markets Ongoing -- -- International Strategy Progressing with CSL Seqirus Partnership for Australia & New Zealand -- -- Leadership Team and New Board of Directors Focused on Shareholder Value Creation -- -- Company to Host Conference Call Today at 8:00 a
ZacksBiotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
- GlobeNewswire
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President & CEO, and members of Amarin’s senior management team to discuss the Company’s first quarter 2023 financial results on Wednesday, May 3rd, 2023 at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s first quarter 2023 financial results in the pre-market hours. C
- GlobeNewswire
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer (CEO). In addition, the board has appointed Oliver O’Connor as a new independent Director of the company. Both appointments are effective immediately. “As the board works quickly t
Simply Wall St.Here's Why We're Not Too Worried About Amarin's (NASDAQ:AMRN) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksAscendis Pharma A/S (ASND) Soars 8.5%: Is Further Upside Left in the Stock?
Ascendis Pharma A/S (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Motley FoolWhy Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today
U.S. stock markets are under heavy pressure today after two reports on job openings and factory orders came in weaker than expected. The key issue at play is a growing concern that the Federal Reserve's rate hiking campaign may spark a deep and long-lasting economic downturn later this year. Topping it all off, OPEC+'s decision to reign in oil supplies this May has stock investors worried that the central bank may have to keep raising rates to tamp down inflation.
- GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- -- Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel -- DUBLIN, Ireland and BRIDGEWATER, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Israel’s Ministry of Health (MOH) Pharmaceuticals Division h
- GlobeNewswire
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today released the following statement: Since joining the company two weeks ago, the new Amarin board has rolled up its sleeves and begun the hard work of creating value for shareholders. We continue to believe that Amarin has tremendous po
- GlobeNewswire
Amarin Announces Board Departures
DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to avoid further proxy contests, all seven independent non-Sarissa board members: Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek and Alfonso “Chito” Zulueta will resign from the Board of Directors, effective immediately. The departing members of the Amarin
BenzingaAmarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Amarin Corporation plc (NASDAQ: AMRN) announced a new analysis from the Vascepa/Vazkepa (icosapent ethyl) cardiovascular outcomes REDUCE-IT study. The study exhibited the effectiveness of Vascepa/Vazkepa in patients with the recent acute coronary syndrome. The post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36%, respectively, in patients with the recent acute coronary syndrome (ACS) without increas
- GlobeNewswire
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -– DUBLIN, Ireland and BRIDGEWATER, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted new in vitro data supporting the potential mechanistic effects of eicosapentaenoic acid (EPA) in reducing cardiovascular events in at-risk patients presented at the joint ACC.23 together with the World Congress of
- GlobeNewswire
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
--Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding-- --Analysis Builds on Consistently Demonstrated Positive Outcomes for VASCEPA/VAZKEPA Across Sub-Populations in REDUCE-IT, Including in Patients with Prior Myocardial Infarction (MI), Prior Revascularization, Prior Peripheral Arterial Disease (PAD) and Diabetes-- DUBLIN, Ireland and BRIDGEWATER, N.J., March 05, 2023 (GLOBE NE
Insider MonkeyAmarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript
Amarin Corporation plc (NASDAQ:AMRN) Q4 2022 Earnings Call Transcript March 1, 2023 Operator: Welcome to Amarin Corporation’s Conference Call to Discuss its Fourth Quarter and Full Year 2022 Financial Results and Operational Update. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at […]
ZacksAmarin's (AMRN) Q4 Earnings and Revenues Beat Estimates
Amarin Corporation's (AMRN) fourth-quarter 2022 earnings and revenues beat estimates; Vascepa sales decline.
- Zacks
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
- Simply Wall St.
Amarin Full Year 2022 Earnings: US$0.26 loss per share (vs US$0.02 profit in FY 2021)
Amarin ( NASDAQ:AMRN ) Full Year 2022 Results Key Financial Results Revenue: US$369.2m (down 37% from FY 2021). Net...
ZacksSarepta (SRPT) Q4 Earnings & Sales Beat Estimates, Stock Up
Sarepta (SRPT) delivers decent fourth-quarter 2022 results. Management confirms that the FDA does not plan to hold an advisory committee meeting for the DMD gene-therapy filing.
- Motley Fool
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript
Welcome to Amarin Corporation's conference call to discuss its fourth quarter and full year 2022 financial results and operational updates. After prepared remarks, we will open the call to your questions.
GlobeNewswireAmarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target -- -- European, International Strategies Advancing At-Pace with Significant Progress Throughout 2022, and Strong Position for 2023 -- -- Company to Host Conference Call Today at 8:00 a.m. EDT -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), to
ZacksPerrigo (PRGO) Beats Q4 Earnings Estimates, Lags on Sales
Perrigo (PRGO) reports mixed fourth-quarter 2022 results. While the company beats the mark on earnings, it misses sales estimates.